LifeMine Therapeutics
LifeMine Therapeutics is a clinical-stage biopharmaceutical company pioneering a bold new approach called Top-Down Drug Discovery™, leveraging evolutionary insights from fungi to develop next-generation precision medicines. The company aims to bring sophisticated medicines to patients in urgent need of breakthrough disease intervention through its data-immersive and technologically expansive discovery engine.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Clinical-stage precision-engineered calcineurin inhibitor (immunosuppressive)
A precision-engineered small-molecule calcineurin inhibitor in clinical development as an immunosuppressive for immune-mediated disorders and organ transplant rejection; advanced to first‑in‑human dosing.
Clinical-stage precision-engineered calcineurin inhibitor (immunosuppressive)
A precision-engineered small-molecule calcineurin inhibitor in clinical development as an immunosuppressive for immune-mediated disorders and organ transplant rejection; advanced to first‑in‑human dosing.
Services
An integrated discovery platform combining fungal genomic mining, computational prioritization and experimental validation to identify and advance small‑molecule leads.
An integrated discovery platform combining fungal genomic mining, computational prioritization and experimental validation to identify and advance small‑molecule leads.
Expertise Areas
- Top-down drug discovery using fungal genomics
- Computational genomics and bioinformatics
- Small-molecule medicinal chemistry and precision inhibitor design
- Structure–activity relationship (SAR) and covalent inhibitor discovery
Key Technologies
- Genomic discovery
- Bioinformatics and machine learning
- Structure–activity relationship (SAR) analysis
- Covalent inhibitor chemistry
News & Updates
April 8, 2025 Press Releases
September 26, 2024 Publications
July 3, 2024 LifeMine Expedition Academy
October 13, 2023 In the News
April 8, 2025 Press Releases
September 26, 2024 Publications
July 3, 2024 LifeMine Expedition Academy
October 13, 2023 In the News